New Report Covers Primary Progressive Multiple Sclerosis (PPMS)-Pipeline Review, H2 2016
Primary Progressive Multiple Sclerosis (PPMS)-Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Primary Progressive Multiple Sclerosis (PPMS) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS), complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Progressive Multiple Sclerosis (PPMS) and features dormant and discontinued projects.
Complete report available @ Primary Progressive Multiple Sclerosis (PPMS)-Pipeline Review, H2 2016
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Primary Progressive Multiple Sclerosis (PPMS)
- The report reviews pipeline therapeutics for Primary Progressive Multiple Sclerosis (PPMS) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Primary Progressive Multiple Sclerosis (PPMS) therapeutics and enlists all their major and minor projects
- The report assesses Primary Progressive Multiple Sclerosis (PPMS) therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Primary Progressive Multiple Sclerosis (PPMS)
- The report reviews pipeline therapeutics for Primary Progressive Multiple Sclerosis (PPMS) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Primary Progressive Multiple Sclerosis (PPMS) therapeutics and enlists all their major and minor projects
- The report assesses Primary Progressive Multiple Sclerosis (PPMS) therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Primary Progressive Multiple Sclerosis (PPMS)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Primary Progressive Multiple Sclerosis (PPMS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Primary Progressive Multiple Sclerosis (PPMS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
F. Hoffmann-La Roche Ltd. Genzyme Corporation Glialogix, Inc. Kyorin Pharmaceutical Co., Ltd. MedDay SA Santhera Pharmaceuticals Holding AG Teva Pharmaceutical Industries Ltd.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 23:37
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home